For Immediate Release

Chicago, IL – August 26, 2009 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sanofi-Aventis (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Baxter (BAX) and Novartis (NVS).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Tuesday’s Analyst Blog:

H1N1 Vaccine to Miss Target

Although we are waiting eagerly for the first H1N1 vaccine to hit the market, it seems production of the vaccine will be much less than the original estimates. According to a warning from the World Health Organization (WHO), supply will be much less than anticipated earlier, especially with the winter season approaching in the northern hemisphere.

Per initial estimates from October onwards, about 94 million doses of vaccine could have been manufactured by the pharmaceutical companies, but this target has already been slashed by 50-75% due to poorer than expected yield from the virus strains.

Almost 25 pharmaceutical companies are racing against time to bring the vaccine to the market. Among these the top five which include, Sanofi-Pasteur of France (the vaccine arm of Sanofi-Aventis [SNY]), AstraZeneca (AZN), GlaxoSmithKline (GSK), Baxter (BAX), and Novartis (NVS) are likely to contribute almost 80% of the total production.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Mark Vickery
Web Content Editor



Zacks Investment Research